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Abstract 
Pulmonary hypertension (PH) is a rare and devastating disease characterized by progressive 
increases in pulmonary arterial pressure and pulmonary vascular resistance, which eventually 
leads to right ventricular failure and death. Pulmonary arterial hypertension (PAH) (World 
Health Organization Group I), a subset of PH, and may be idiopathic in nature or associated with 
other systemic conditions and is thought to most commonly effect women, the majority of whom 
are of childbearing age. However, PAH in the elderly population is being increasingly diagnosed 
creating clinical considerations that had once not been considered. Often in an elderly population 
the diagnosis of PAH may be delayed due to chronic comorbid conditions such as coronary 
artery disease or other dyspneic conditions. Though survival and clinical outcomes have 
improved, the elderly population continues to have disproportionately lower survival rates. High 
clinical suspicion of PAH warrants a complete diagnostic workup with right heart 
catheterization. Upon diagnosis, PAH specific therapy should be initiated with possible drug 
interactions in mind. Adjuvant pulmonary rehabilitation should be considered as a conservative 
measure with definitive results. Finally, psychosomatic aspects of the disease should also be 
considered in elderly populations. 
Key words: pulmonary hypertension, pulmonary arterial hypertension, pulmonary 
hypertension in the elderly, geriatric medicine, pulmonary vascular disease  
  
Introduction 
Pulmonary hypertension (PH) is a rare and devastating disease characterized by 
progressive increases in pulmonary arterial pressure and pulmonary vascular resistance, which 
eventually leads to right ventricular failure and death [1, 2]. Pulmonary hypertension is defined 
hemodynamically as a mean resting pulmonary artery pressure (mPAP) greater than or equal to 
25 mmHg as confirmed by right heart catheterization (RHC). The World Health Organization 
(WHO) has proposed a classification system for PH based on common clinical features and 
etiology, which is outlined in Table 1 [3]. Regardless of classification efforts, PH remains to be a 
clinical challenge due to its complex pathogenesis, limited disease specific therapies and 
healthcare disparities [4].  
Pulmonary arterial hypertension (PAH) (WHO Group I PH), may be idiopathic in nature 
or associated with connective tissue diseases, congenital heart disease, portal hypertension, HIV 
or drug induced and is thought to most commonly effect women, the majority of whom are of 
childbearing age [3, 5, 6]. Due to disease recognition and readily available advanced diagnostic 
modalities, PAH in the elderly population is being increasingly diagnosed. Recent data has 
shown that there was a shift in the demographics of PAH with initial diagnosis coming at an 
older age, creating clinical considerations once not thought of [7, 8]. Though the underlying 
causes of PAH are well studied, in the elderly it presents a clinical challenge to the standard 
therapeutic algorithm. This review article will serve to describe the changing epidemiology and 
challenges clinicians face in the diagnosis and management of PAH in the elderly population. 
 
Methods 
A comprehensive literature search was conducted of the National Library of Medicine’s 
MEDLINE/PubMed with the objective of identifying all articles published in the English 
language between January 1980 and May 2018 with “elderly” and “pulmonary arterial 
hypertension” in the title. Combinations of medical subject heading terms including “pulmonary 
arterial hypertension,” “changes with age” and “management of pulmonary hypertension in the 
elderly” were used. Recent publications were mainly selected, but older works were not excluded 
provided that they were widely referenced. Reference lists were also searched of all articles 
identified by this search strategy and those that were judged to be relevant were also selected. All 
pertinent reports were retrieved and the relative reference lists were systematically searched in 
order to identify any potential additional studies that could be included. All data were accessed 
between January 2017 and May 2018. 
 
General considerations 
Pulmonary arterial hypertension is characterized by a specific pattern on pulmonary 
hemodynamics. During RHC, there is an added criterion of  pulmonary capillary wedge pressure 
(PCWP) ≤ 15 mmHg) with an absolute increase in pulmonary vascular resistance (PVR) (> 3 
WU), and is labeled as pre-capillary PH [9]. Histologically, this group of conditions is 
characterized by vascular specific changes such as endothelial and fibroblast dysfunction. These 
molecular level changes affect different pathways implicated in the specific therapy of PAH. 
Among them are the nitric oxide, endothelin and prostacyclin pathways. 
The health care burden of PH has also increased in the recent decades [10]. Secondary 
causes of PH are the still the most common in the elderly population such as PH due to left heart 
disease (WHO Group 2 PH) and PH due to lung disease/hypoxia (WHO group 3 PH) [11]. The 
incidence of PH with heart failure with preserved ejection fraction (HFpEF) was noted to be 
between 36% to 83% based on recent studies [12–14]. In contrast to pre-capillary PH (PAH), left 
heart disease causes post-capillary PH secondary to backward transmission of elevated left-sided 
filling pressures into the pulmonary circulation. These patients may demonstrate either isolated 
post-capillary PH or combined post-capillary PH along with a component of pre-capillary PH. In 
these patients, invasive hemodynamics show a combination of elevated PCWP and increased 
PVR [9]. Thus, despite the presence of clear definitions an increasing number of patients are 
noted to have simultaneous existence of multiple categories of PH. This is especially relevant in 
the elderly population who have a have increased co-morbidities associated with HFpEF such 
has arterial hypertension, atrial fibrillation and age related diastolic dysfunction.  
Pulmonary arterial hypertension remains a relatively rare diagnosis in the elderly as well 
as WHO Group IV, chronic thromboembolic PH (CTEPH) [15]. In the elderly, management of 
PH due to secondary causes is dictated by the etiology and disease severity. Diagnosis in the 
elderly is often elusive due to non-specific findings including shortness of breath, fatigue, 
weakness, angina and syncope; these symptoms are largely due to right ventricular dysfunction 
[9]. In a study by Shapiro et al. [16] examining unexplained PH in the elderly population it was 
found that despite in the absence of secondary causes of PH the elderly population did not meet 
the diagnostic hemodynamic criteria for PAH due to elevated PCWP [16]. A strong clinical 
suspicion and complete diagnostic workup including a RHC should be considered if PAH is in 
the differential. 
 
Epidemiology  
Traditionally it has been thought that PAH is a disease of the young, however, studies 
have shown that the number of elderly patients (age ≥ 65 years) being diagnosed with PAH is 
increasing. United States registry data suggests that PAH has an older age at diagnosis as 
compared with the National Institute of Heath registry study performed in the 1980s, with nearly 
17% of the cohort 65 years of age at the time of diagnosis in the last decade [17–19]. A 
multinational European registry has found that up to 63% of patients in a cohort of PAH were 
aged 65 years or older [8]. Baseline characteristics of PAH patients across various registries has 
been outlined in Table 2 [7, 8, 18–23]. 
There appears to be a trend of diagnosis of PAH occurring at a later age (Fig. 1). In the 
latest epidemiological registry results, it was found by Mueller-Mottet et al. [23] that since 2000, 
the age of Swiss PAH patients has been gradually getting older. A study by Hoeper et al. [8], the 
Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension 
(COMPERA) revealed the highest median age (71 ± 16 years) at diagnosis was reported in the 
literature with a majority of patients being of the elderly population. The Registry to Evaluate 
Early And Long-term PAH Disease Management (REVEAL) found that being a male greater 
than 60 years of age showed an increased risk of mortality [24]. This observed trend may due to 
various reasons including delay in diagnosis as it is known that the mean duration between 
symptom onset and diagnostic catheterization has been reported to be approximately 2.8 years 
[18]. In the elderly population, this may hold especially true due to the rare nature of the disease 
and presence of other comorbid dyspneic conditions such as chronic obstructive pulmonary 
disease (COPD) and coronary artery disease (CAD). In a study by Shimony et al. [25] it was 
found that in the cohort of patients age 65 and older there was a 4.6 times greater prevalence of 
significant CAD than those individuals less than age 65, which may lead to dyspnea and further 
delay the diagnosis of PAH. Delays in diagnosis may be detrimental as elderly patients tend to 
present at a worse functional class, which may due to their underlying comorbidities or even 
extrinsic factors such as socioeconomic status [26, 27].  
 
Diagnostic considerations 
The diagnosis of PH requires a high degree of clinical suspicion based on symptoms and 
physical examination. This is followed by a comprehensive set of investigations to assess the 
hemodynamics as well as to determine the etiology of the disease process. Basic work up 
includes electrocardiogram, chest radiograph, pulmonary function tests, 6-minute walk distance 
(6WMD), arterial blood gas, echocardiography, ventilation/perfusion scan and high-resolution 
computed tomography [6]. It is also important to assess for left atrial pressures to rule out group 
II PH. Pressure measurements include PAP measurements and PCWP as a surrogate of left atrial 
pressure. Derived variables include calculating a PVR and transpulmonary pressure gradient 
(TPG). A PVR > 3WU is required for diagnosis of PAH. TPG is calculated as the difference 
between mPAP and PCWP and has been used to distinguish ‘passive’ PH (TPG < 12 mmHg) 
from ‘reactive’ PH (TPG ≥ 12). Unfortunately, the limitation of this measurement is that it is 
influenced by multiple determinants of mPAP including flow, resistance and left heart filling 
pressures. Diastolic PAP on the other hand is less influenced by PCWP at any level of stroke 
volume. Therefore the 2015 PH guidelines recommends diastolic pulmonary gradient (DPG) 
defined as diastolic PAP — mean PCWP as the best approach to determine the presence of 
pulmonary vascular disease. Thus in a patient with mPAP ≥ 25 mmHg and PCWP > 15mm Hg, a 
DPG < 7 mmHg and/or PVR ≤ 3 WU reflects the presence of isolated post-capillary PH while a  
DPG ≥ 7 mmHg and/or PVR > 3 WU represents combined post-capillary and pre-capillary PH.   
Pulmonary vasoreactivity testing during the RHC is also considered for patients with 
PAH. A positive response is defined as reduction of mPAP > 10 mmHg to reach an absolute 
value of mPAP of ≤ 40 mmHg with an increased unchanged CO. Coronary angiography should 
be considered in patients with risk factors of CAD or in patients being listed for pulmonary 
endarterectomy or lung transplantation [28].  
 
Management 
At present curative options for PAH are limited to lung transplantation which in the 
elderly has shown to carry an increased risk of mortality [29]. However, over the past decade 
targeted pharmaceutical options have become available for the treatment of PAH (Table 3) [9, 
30]. There are different classes of medications available with different mechanisms of actions, all 
of which net a vasodilatory and anti-proliferative effect [9, 30]. If PH is suspected all efforts 
must be made to exclude secondary causes. Once a definitive diagnosis of PAH has been made 
with RHC, drug specific therapy should be initiated. Certain considerations should be observed 
in this population relating to therapeutic response. In general, elderly patients are weaker 
responders to vasodilatory effects which may due to age related vascular stiffening of the 
pulmonary arteries. It has been shown that a significant age-related increase in pulmonary artery 
systolic pressure exists and increases about 1 mmHg annually [31, 32]. Additional special 
considerations need to be taken in the geriatric population while using PAH specific therapy. 
These considerations set forth by the Food and Drug Administration have been outlined in Table 
4 [33]. 
Pharmacotherapy of PAH should be addressed in a cautious way.  A majority of patients 
of the elderly age group diagnosed with PAH also tend to have underlying chronic comorbidities. 
In the United Kingdom PAH registry, it was found that in patients greater than age 50, nearly all 
patients suffered from systemic hypertension, more than half from diabetes as well as ischemic 
heart disease [7]. These patients should have their co-morbid conditions managed optimally to 
reduce the synergistic effects on PAH.   
In the elderly population, delayed diagnosis usually means advanced disease at 
presentation. With evidence pointing towards initial combination therapy, the use of multiple 
drugs working on multiple PAH pathways creates the possibility of drug-drug interactions in the 
elderly population. The PDE-5 sildenafil is metabolized via the cytochrome P450 pathway 
specifically involving CYP3A4 and CYP2C9. There is an increase in sildenafil bioavailability 
and reduced clearance with CYP3A4 substrates and inhibitors and CYP3A4 substrates plus beta-
adrenoceptor blockers. Drugs that are CYP3A4 inducers such as barbiturates, rifampicin and St. 
John’s wort may lower sildenafil levels and should be used with caution. Sildenafil levels are 
modestly increased by fresh grapefruit juice, a weak inhibitor of CYP3A4 [34].  
The ERA bosentan is an inducer of cytochrome P450 isoenzymes CYP3A4 and CYP2C9. 
Plasma concentrations of drugs metabolized by these isoenzymes will be reduced when co-
administered with bosentan. Of note is that the combination of a potent CYP3A4 inhibitor 
(ketoconazole, ritonavir) and/or a CYP2C9 inhibitor (e.g. amiodarone, fluconazole) with 
bosentan may cause a significant increase in plasma bosentan levels and thus is contraindicated. 
Interactions may theoretically occur with certain antifungals as well as immunosuppressive 
drugs. It is also important to note that bosentan is often administered concomitantly with 
sildenafil as part of dual PAH therapy. It has been found that bosentan significantly decreases the 
plasma concentration of sildenafil when co-administered to patients with PH [35]. A detailed 
outline of PAH specific medications and interactions with commonly used drugs is shown in 
Table 5 [36]. 
Currently there are no guidelines on treatment of PAH specifically in the elderly. 
Treatment of PAH is dictated by WHO functional class at presentation [9, 30]. However there 
has been a trend towards the use of oral medications such as Bosentan over intravenous or 
inhalation prostacyclins, possibly due to the ease of use and compliance [25]. In addition, it has 
been observed that there is a tendency to use monotherapy in the elderly as observed in the 
COMPERA trial as well as in the United Kingdom population [8]. 
Another aspect to consider in pharmacotherapy treatment of elderly patients diagnosed 
with PAH is the presence of risk factors for concurrent left heart disease. Several registries have 
documented a change in phenotype of patients with PAH with increasing age [7, 8]. The terms 
typical and atypical PAH have been proposed to distinguish between these two populations [12]. 
Opitz et al. [12] in their review of the COMPERA trial, noted that patients with atypical PAH 
share features of both typical PAH and PH-HFpEF indicating that there might be a continuum 
between these conditions. Multiple studies have demonstrated that these patients with risk factors 
of left heart disease presenting with pre-capillary PH (atypical PAH) may benefit from targeted 
therapies [12, 28, 37, 38]. Opitz et al. [12] also demonstrated the potential benefits of targeted 
PH therapies in patients with HFpEF and combined post-capillary and pre-capillary PH. 
Thus, future studies are warranted to identify treatment strategies for this patient 
population. This is especially important in the elderly population, as there is a growing number 
of PH-HFpEF patients diagnosed as PAH, and the efficacy of specific PAH therapy may decline 
and side effects may become more prominent. 
 
Pulmonary rehabilitation 
Pulmonary rehabilitation (PR) is defined as a comprehensive intervention based on a 
thorough patient assessment followed by patient-tailored therapies, which include, but are not 
limited to, exercise training, education, and behavior change, all designed to improve the 
physical and psychological condition of people with chronic respiratory disease and to promote 
long-term adherence of health-enhancing behaviors [39]. The primary goal of PR programs is to 
improve function, disease related symptoms, optimize functional capacity and an overall 
improvement in quality of life (QoL) [40]. A multinational European study by Spruit et al. [41] 
found that there are still large differences among PR programs across continents. Their findings 
stress the importance of future development of processes and performance metrics to monitor PR 
programs to begin standardization, and to provide recommendations for internationally evidence 
based guidelines.  
Pulmonary rehabilitation has been well-studied and has been demonstrated to reduce 
dyspnea, increase exercise tolerance and improve health-related QoL in patients with COPD and 
idiopathic pulmonary fibrosis in the elderly [39, 42, 43].  While there are fewer trials of PR in 
patients with PAH, they also show that PR improves exercise capacity, muscle strength and 
health-related QoL [44]. A recent study by Talwar et al. has shown that patients across all groups 
of PHTN with an average age of 67.7 ± 11.6 years there was improvement in exercise tolerance 
as measured by miles per hour. Being that PR is a conservative treatment, philosophy dictates 
consideration in pharmacologically optimized PAH patients, utilization in the elderly population 
may be beneficial. It may also be beneficial in patients who have been deemed unable to receive 
pharmacotherapy. Though these small trials have provided beneficence in an elderly population, 
certain precautions must be taken prior to initiation, including a pulmonary and cardiac 
clearance.  
Several studies have also found that PR improves numerous clinical endpoints. Mereles 
et al. [45], found that 30 patients with either idiopathic PAH or CTEPH experienced 
improvements in 6MWD and QoL self-assessment scores; importantly, rehabilitation was well-
tolerated and deemed to be safe. Another study found an improvement in 6MWD, resting heart 
rate, peak oxygen consumption, oxygen saturation and systolic pulmonary artery pressure in 
patients with PH due to connective tissue disease [46]. Though these study cohorts were not 
exclusively elderly patients it may be inferred that they provide a similar benefit.  
 
Psychosomatic considerations 
Pulmonary arterial hypertension is a debilitating lung disease characterized exertional 
dyspnea, exercise intolerance, palpitations, fatigue and even syncope. Besides the somatic effects 
of the disease the elderly population is more averse to the psychological effects of the disease. In 
the elderly population where disease severity may be at a peak or pharmacotherapy 
contraindicated, improving psychosomatic manifestations of the disease may be the only option. 
Assessing psychological and somatic effects of the disease may be difficult, however with the 
use of a standardized instrument may be advantageous. Recently the PAH-SYMPACT 
questionnaire demonstrated to be a valid patient self-reporting tool to measure the impact that 
PAH is having on an individual [47].  
It has been well documented that depression and diminished mental functioning are part 
of the PAH picture [40, 48]. In addition, disease-specific symptoms such as shortness of breath 
can adversely affect health related QoL (HRQoL), increase anxiety and be independently related 
to depression [49–51]. HRQoL in patients with PAH has been shown to be correlated with 
6MWD and may affect WHO functional class status [51]. Worsening HRQoL and depressive 
symptoms may result in a decrease in physical activity, which reduces exercise tolerance and 
worsens dyspnea — this notion is supported by evidence that exercise and PR has been 
demonstrated to improve exercise capacity and WHO functional class [46, 52]. As noted above, 
dyspnea is independently related to depressive symptoms; another study that patient self-reported 
dyspnea negatively correlates with a reduced mental and physical QoL [40]. Taken together, the 
evidence supports the possibility of a “vicious cycle” of worsening dyspnea resulting in 
decreased exercise tolerance and worsening depressive symptoms, leading to decreased HRQOL 
which then decreases physical activity further, perpetuating the cycle as the disease progresses.  
Considerations of the relationship between dyspnea, HRQoL and depression are of 
particular note in the elderly as depression is already a significant problem in this population: 5% 
of community-dwelling older adults suffer from major depressive disorder and 8% to 16% of 
older adults have clinically significant depressive symptoms [53]. Furthermore, rates of major 
depressive disorder rise as medical morbidity increases. Jackson et al. [54] found that up to 37% 
of patients suffer from major depressive disorder after critical care hospitalizations. Therefore, it 
is important for practitioners to recognize depression in elderly patients with PH and provide 
appropriate interventions.  
Another psychosomatic aspect of PAH, often overlooked, in the elderly is fatigue. 
Fatigue is defined as extreme, persistent tiredness and mental, physical weakness or exhaustion 
and represents a psychosomatic domain of the disease [55, 56].  In the setting of PH fatigue may 
have a multifactorial etiology, including many conditions that can underlie PH or be associated 
with PH such as heart failure, obstructive sleep apnea, depression, muscle weakness and 
osteoporosis, so recognition and effective treatment of other contributing factors is important 
[57]. The studies of fatigue in PAH are rare, however in a study by Sahni et al. [58] a cohort of 
42 patients comprised of all WHO groups of PH, there was an elevated level of fatigue as 
measured by the fatigue severity scale. In an another study, Talwar et al. [57] found that in a 
cohort of 21 patients with a mean age 64.3 years with advanced lung disease (COPD and ILD) 
there was an elevated level of fatigue as measured by the Fatigue Severity Scale and also an 
improvement in fatigue symptoms after completion of a PR program.  
 
Survival 
Over the past decades, with the advent of PAH specific drugs, in general the outcomes of 
PAH have improved [59]. However, the elderly cohort is unique in that survival of PAH patients 
is not as favorable as in  younger populations, which may be multifactorial. In an analysis of 587 
patients from the COMPERA registry all-cause mortality was 18.4%. There were 108 deaths; 25 
(mortality rate, 12.0%) in the younger cohort (< 65 years of age) and 83 (mortality rate, 22.0%) 
in the older one (p = 0.003) and in younger patients, the 1-, 2-, and 3-year survival rates were 
96.0%, 90.9% and 83.3%, respectively. The corresponding survival rates in the older patients 
were 89.8%, 78.6% and 68.0% [8]. The authors attributed the lower survival rate in the elderly 
cohort to limited response to pharmacotherapy and a less aggressive approach relying on 
monotherapy over combination therapy. In a study that analyzed data from 6 randomized 
treatment trials patients were categorized into three age groups following traditional cut-offs (≤ 
50, 50–65, and ≥ 65 years old). It was found though that mortality rates were generally lowacross 
the groups, there was a significantly higher rate of mortality as age groups increased, mortality 
rates were 16.6%, 24.6% and 28.6% in the three age groups, respectively (p = 0.0004) [27].   
 
Conclusions 
Pulmonary arterial hypertension in the elderly remains to be a rare diagnosis, however it 
is becoming more recognized. Often in an elderly population the diagnosis of PAH may be 
delayed due to chronic comorbid conditions such as CAD or other dyspneic conditions. Though 
survival and clinical outcomes have improved, the elderly population continues to have 
disproportionately lower survival rates. A high clinical suspicion of PAH warrants a complete 
diagnostic workup with right heart catheterization. Upon diagnosis of PAH, specific therapy 
should be initiated with possible drug interaction in mind. Adjuvant PR should be considered as 
a conservative measure with definitive results. Finally, psychosomatic aspects of the disease 
should also be considered in an elderly population.  
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Table 1. World Health Organization Classification of Pulmonary Hypertension 
Group I. Pulmonary arterial hypertension (PAH)  
Idiopathic PAH 
Heritable PAH (BMPR2, ALK1, endoglin, SMAD9, caveolin-1, KCNK3, unknown) 
Drug and toxin induced 
Associated with (i) Connective tissue disease, (ii) HIV infection, (iii) Portal hypertension, (iv) 
Congenital heart disease, (v) Schistosomiasis 
Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis 
Persistent pulmonary hypertension of the newborn  
Group II. Pulmonary hypertension due to left heart disease 
Left ventricular systolic dysfunction 
Left ventricular diastolic dysfunction 
Valvular disease 
Congenital/acquired left heart inflow/outflow tract obstruction and congenital cardiomyopathies 
Group III. Pulmonary hypertension due to lung diseases and/or hypoxia  
Chronic obstructive pulmonary disease  
Interstitial lung disease  
Other pulmonary diseases with mixed restrictive and obstructive pattern 
Sleep-disordered breathing  
Alveolar hypoventilation disorders  
Chronic exposure to high altitudes  
Developmental lung disease  
Group IV. Chronic thromboembolic pulmonary hypertension 
Group V. Pulmonary hypertension with unclear multifactorial mechanisms 
Hematologic disorders: chronic hemolytic anemia, myeloproliferative disorders, splenectomy 
Systemic disorders: sarcoidosis, pulmonary histiocytosis, lymphangioleimyomatosis 
Metabolic disorders: glycogen storage disease, Gaucher’s disease, hypothyroidism  
Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure, segmental pulmonary 
hypertension 
5th World Symposium on Pulmonary Hypertension, Nice, France 2013 
BMPR — bone morphogenic protein receptor type II; HIV — human Immunodeficiency virus 
 
Table 2. Baseline epidemiologic characteristics of pulmonary arterial hypertension registries 
Registry NIH  French US REVEAL UK/Ireland ASPIRE COMPERA Swiss 
Year 1987 2006 2007 2010 2012 2012 2013 2015 
Number 187 674 578 2525 482 175 587 171 
Mean age at 
diagnosis 
[years] 
36±15 50±15 48±14 50.1±14.4 50.1±17.1 55±16 71±16 60±15 
Women [%] 63.0 65.3 77.0 55.6 69.9 67.0 60.3 56.0 
 
 
 
Table 3. Medications in the management of pulmonary arterial hypertension (PAH) 
PAH specific therapies Mode of administration 
Phosphodiesterase type-5 (PDE) inhibitors 
Sildenafil (Revatio) Oral 
Tadalafil (Adcirca) Oral 
Prostacyclin analogues 
Epoprostenol (Flolan, Valetri) Intravenous infusion, injection 
Treprostinil (Remodulin, Tyvaso, Orenitram) Intravenous infusion, inhalation, oral 
Iloprost (Ventavis) Inhalation 
Prostacyclin receptor agonist 
Selexipag (Uptravi) Oral 
Endothelin receptor antogonists (ERAs) 
Bosentan (Tracleer) Oral 
Ambrisentan (Letairis, Volibris) Oral 
Macitentan (Opsumit) Oral 
Soluble guanylate cyclase (sGC) stimulator 
Riociguat (Adempas) Oral 
 
 
 
Table 4. Geriatric considerations of select pulmonary arterial hypertension specific medications. 
Drug Geriatric consideration 
Sildenafil Clinical studies of did not include sufficient numbers of subjects aged 65 
and over to determine whether they respond differently from younger 
subjects. Other reported clinical experience has not identified differences in 
responses between the elderly and younger patients. 
Tadalafil No overall differences in safety were observed between subjects over 65 
years of age compared to younger subjects or those over 75 years of age. 
Riociguat No overall differences in safety or effectiveness were observed between 
elderly and younger subjects. 
Bosentan No conclusive evidence from clinical trials. 
Ambrisentan The elderly (age ≥ 65 years) showed less improvement in walk distances 
with Letairis than younger patients did. Peripheral edema was more 
common in the elderly than in younger patients. 
Improvements in walk distance with Letairis were smaller for elderly 
patients (age ≥ 65) than younger patients. 
Peripheral edema was greater in elderly patients (age ≥ 65) receiving 
Letairis as compared to placebo. 
Mactitentan No overall differences in safety or effectiveness were observed between 
these subjects and younger subjects. 
Epoprostenol/ilopr
ost/treprostinil 
No conclusive evidence from clinical trials or clinical experience. In 
general, dose selection for an elderly patient should be cautious, usually 
starting at the low end of the dosing range, reflecting the greater frequency 
of decreased hepatic, renal, or cardiac function and of concomitant disease 
or other drug therapy. 
Selexipag No overall differences were observed between these subjects and younger 
subjects, and other reported clinical experience has not identified 
differences in responses between the elderly and younger patients 
All considerations obtained from Federal Drug Administration (FDA) drug approved package 
inserts. 
 
Table 5. Potential interactions between pulmonary arterial hypertension–specific medications for concurrent illnesses. 
 Anti–
platelets 
anticoagu
lants 
Stati
ns 
Digo
xin 
NSAI
Ds 
SSR
Is/T
CAs 
Sul
ph. 
Beta–
block
ers 
Bar
bitu
ates 
Macrol
ides 
Protea
se 
Inhibi
tors 
An
tifu
nga
ls 
Cyclo
spori
ne A 
Hormonal 
contracepti
ves 
Prostacyclin analogues 
Epoprostenol X – – – – – – – – – – – – 
Treprostinil X – – X – – – – – – – – – 
Iloprost X – – – – – – – – – – – – 
Phosphodiesterase type–5 inhibitors 
Sildenafil – – – – – X – – X X X – – 
Tadalafil – – – – – – – – X – X – – 
Endothelin receptor antagonists 
Bosentan X X – – – X – X X X X X X 
Macitentan – – – – – – – X X X X X X 
Ambrisentan – – – – – – – – X – – – – 
Soluble guanylate ciclase stimulator  
Riociguat – – – –  X – X X – X – – 
NSAID — non–steroidal anti–inflammatory drug; SSRI — serotonin–selective re–uptake inhibitor; TCA — tricyclic acid; X — 
known interaction; ″–″ no known interaction or not clinically significant interaction 
 
 
Figure 1. Chronological display of average age of diagnosis in pulmonary arterial hypertension registries. 
 
 

